- Zacks•39 minutes ago
With the second quarter earnings season in full swing, several biotech companies including Amgen (AMGN) will be reporting this week.
- Market Realist•4 hours ago
Since the launch of Sovaldi in late 2013, Gilead Sciences has managed to treat about 1,000,000 hepatitis C (or HCV) patients globally.
Gilead Sciences Inc.NasdaqGS
After hours: 81.870.08 (0.10%) as of 4:03 PM EDT
|Bid||81.65 x 1000|
|Ask||81.66 x 1300|
|52wk Range||77.92 - 120.37|
|Day's Range||81.06 - 81.98|
|Avg Vol (3m)||10,165,517|
As of 4:00 PM EDT. Market closed.